F. Kroschinsky

Model-based integration of chimeric antigen receptor T-cell kinetics and tumor features to predict therapeutic outcomes in patients with B-cell malignancies

Introduction Chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for several hematological malignancies, yet patient-specific responses and toxicities remain hard to predict. Although multiple covariates and risk scores exist, their prognostic accuracy remains limited. Methods We prospectively measur...